• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    SC 13G 1 tevogen13g.htm



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

    Tevogen Bio Holdings Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     

     88165K101
    (CUSIP Number)
     
    February 14, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    Persons who respond to the collection of information contained
    in this form are not required to respond unless the form
    displays a currently valid OMB control number.

    CUSIP No.
    88165K101
    13G
     
     
     
    1
    NAMES OF REPORTING PERSONS
     
     
     
     
     
    Manmohan Patel
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a) ☐
     

    (b) ☐
     

    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    646,412
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    8,628,077
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    646,412
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    8,628,077
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,274,489
     
     
     
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐

           
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.6%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON*
     
     
    IN
     
     
     
     

    (1)
    Calculated based on 164,614,418 shares of Common Stock outstanding as of Febuary 22, 2024 as disclosed in the Schedule 13D filed by Ryan H. Saadi on February 22, 2024.





    CUSIP No.
    88165K101
    13G
     
     

     Item 1(a)
     Name of Issuer:
     
     
     
    The name of the issuer is Tevogen Bio Holdings Inc. (the “Issuer”).
     
     
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
     
     
     
    15 Independence Boulevard, Suite #410, Warren, New Jersey 07059.
     
     
    Item 2(a)
    Name of Person Filing:
     
     
     
    Manmohan Patel
     
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
     
     
     
    5 Jennie Court, Cedar Grove, NJ 07009
     
     
    Item 2(c)  Citizenship:
       
     
    United States 
       
    Item 2(d)
    Title of Class of Securities:
     
     
     
    Common Stock
     
     
    Item 2(e)
    CUSIP No.:
     
     
     
    88165K101
     
     
    Item 3
    If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
     (a) ☐ 
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     (b) ☐ 
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     (c) ☐ 
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     (d) ☐ 
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     (e) ☐ 
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
     (f) ☐ 
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
     (g) ☐ 
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
     (h) ☐ 
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     (i) ☐ 
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     (j) ☐ 
    A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
     (k) ☐ 
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .



    Item 4
    Ownership:


    Tevogen Bio Holdings Inc.

     
    (a)
      Amount beneficially owned: 9,274,489
     
     
    (b)
      Percent of class:  5.6%
     
     
    (c)
      Number of shares as to which such person has: 
     
     
    (i)
      Sole power to vote or direct the vote:  646,412
     
     
     
    (ii)
      Shared power to vote or direct the vote: 8,628,077
     
     
     
    (iii)
      Sole power to dispose or direct the disposition: 646,412
     
     
     
    (iv)
      Shared power to dispose or direct the disposition: 8,628,077

    Item 5
    Ownership of Five Percent or Less of a Class:
       


     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.
     
    Item 6 Ownership of More Than Five Percent on Behalf of Another Person:


     
     Not applicable.


    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
     
     
    Not applicable.
     
     
    Item 8
    Identification and Classification of Members of the Group:
     
     
     
    Not applicable.
     
     
    Item 9
    Notice of Dissolution of Group:
     
     
     
    Not applicable.
     
     
    Item 10
    Certification:
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date: March 4, 2024

           Manmohan Patel  
             
           /s/ Manmohan Patel  
           Manmohan Patel  

       


     
     



    Get the next $TVGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Tevogen Bio with a new price target

      D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

      3/4/25 8:26:08 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

      WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models." This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (NASDAQ:MSFT) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developin

      7/18/25 12:36:44 PM ET
      $MSFT
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

      WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company's cell therapy manufacturing operations. This state-of-the-art facility aligns with Tevogen's strategic goals of accelerating clinical development while maintaining cost efficiency and scalability. The facility's intended use will be for GMP cell therapy manufacturing and complement Tevogen's anticipated growing pipeline powered by PredicTcell™, the

      7/17/25 9:15:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and g

      7/16/25 6:35:00 PM ET
      $MSFT
      $PSNL
      $TEM
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Medical Specialities
      Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saadi Ryan H. was granted 8,000,000 shares, increasing direct ownership by 7% to 124,814,453 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:49:36 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Khan Sadiq was granted 200,000 shares, increasing direct ownership by 21% to 1,169,618 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:49:18 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Desai Kirti was granted 750,000 shares, increasing direct ownership by 8% to 10,449,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      7/1/25 4:48:42 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    SEC Filings

    See more
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      7/10/25 9:18:41 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Holdings Inc. filed SEC Form 8-K: Other Events

      8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      7/10/25 9:15:56 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      7/3/25 5:25:45 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/14/24 5:29:01 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/12/24 4:28:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

      SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      3/4/24 4:24:14 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Financials

    Live finance-specific insights

    See more
    • Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

      WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

      2/14/25 1:16:54 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

      WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e

      8/22/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

      WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com

      8/15/24 9:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/29/25 8:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/14/25 1:53:50 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

      WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a

      3/26/25 3:12:23 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care